APA
Levy A., Albiges-Sauvin L., Massard C., Izzedine H., Ederhy S., Edhery S., Bahleda R., Gomez-Roca C., Chargari C., Brocheriou-Spelle I. & Soria J. (20120920). Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. : Investigational new drugs.
Chicago
Levy Antonin, Albiges-Sauvin Laurence, Massard Christophe, Izzedine Hassan, Ederhy Stéphane, Edhery Stéphane, Bahleda Ratio, Gomez-Roca Carlos, Chargari Cyrus, Brocheriou-Spelle Isabelle and Soria Jean-Charles. 20120920. Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. : Investigational new drugs.
Harvard
Levy A., Albiges-Sauvin L., Massard C., Izzedine H., Ederhy S., Edhery S., Bahleda R., Gomez-Roca C., Chargari C., Brocheriou-Spelle I. and Soria J. (20120920). Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. : Investigational new drugs.
MLA
Levy Antonin, Albiges-Sauvin Laurence, Massard Christophe, Izzedine Hassan, Ederhy Stéphane, Edhery Stéphane, Bahleda Ratio, Gomez-Roca Carlos, Chargari Cyrus, Brocheriou-Spelle Isabelle and Soria Jean-Charles. Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. : Investigational new drugs. 20120920.